Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Profile Name | RAD51B mutant |
Gene Variant Detail | |
Relevant Treatment Approaches |
Molecular Profile | Indication/Tumor Type | Response Type | Relevant Treatment Approaches | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|---|
RAD51B mutant | ovary serous adenocarcinoma | predicted - sensitive | Cediranib + Olaparib | Clinical Study - Cohort | Actionable | In a Phase II trial, Cediranib (AZD-2171) and Lynparza (olaparib) treatment was well tolerated, and resulted in an objective response (OR) of 9% (all partial), a 16-week progression-free survival (PFS) of 47%, and a disease control rate (DCR) of 68% in heavily pretreated high-grade serous ovarian cancer patients (n=34), and a median PFS of 4.8 months in patients (n=14) harboring mutations in either BRCA1, BRCA2, or RAD51B (PMID: 32444417; NCT02681237). | 32444417 |